Merck Drug Shows Improved Odds for Melanoma Patients

Merck’s new cancer drug Keytruda improved the survival odds of patients with the skin cancer melanoma compared with Bristol-Myers Squibb’s Yervoy, in the first head-to-head study of a new wave of drugs that harness the body’s immune system to destroy tumors

Speak Your Mind

Subscribe to get this amazing EBOOK FREE

Real Estate 101 - Buying Your First Home!

By subscribing to this newsletter you agree to our Privacy Policy